

CURRICULUM VITAE

Ronald Levy, M.D.

PERSONAL DATA

Business Address Division of Oncology, CCSR 1105
Stanford University Medical Center
Stanford, California 94305-5151

ACADEMIC HISTORY

1963 Harvard University, A.B.

1968 Stanford University, M.D.

Post-Doctoral And Residency Training

1968 – 1970 Internship and Residency in Internal Medicine, Massachusetts
General Hospital, Boston, Massachusetts

1970 – 1972 Clinical Associate, Immunology Branch, National Cancer Institute

1972 – 1973 Fellow, Department of Medicine, Division of Oncology, Stanford
University Medical Center, Stanford, California

1973 – 1975 Fellow of the Helen Hay Whitney Foundation, Department of
Chemical Immunology, The Weizmann Institute of Science,
Rehovot, Israel

Certification And Licenses

1970 Commonwealth of Massachusetts

1973 Board Certification, Internal Medicine

1975 State of California Medical License #G021994

1979 Board Certification, Medical Oncology

EMPLOYMENT HISTORY

1970 – 1972	Clinical Associate, Immunology Branch, National Cancer Institute, Bethesda, Maryland
1975 – 1981	Assistant Professor of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California
1981 – 1987	Associate Professor of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California
1987 – Present	Professor of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California
1987 – Present	Robert K. Summy and Helen K. Summy Professor, Stanford University School of Medicine, Stanford, California
1987 – Present	Frank and Else Schilling American Cancer Society Clinical Research Professor
1993 – Present	Chief of the Division of Oncology, Stanford University School of Medicine, Stanford, California

POST-DEGREE HONORS AND AWARDS

1977 - 1982	Investigator, Howard Hughes Medical Institute
1979	Member, American Society of Clinical Investigation
1982	Armand Hammer Award for Cancer Research
1983	Ciba-Geigy/Drew Award in Biomedical Research
1987	Association of American Physicians
1987	American Cancer Society Clinical Research Professor
1989	Dr. Josef Steiner Prize for Cancer Research
1997	Joseph H. Burchenal Clinical Cancer Research Award, American Association for Cancer Research
1999	Karnofsky Award, American Society of Clinical Oncology
1999	Charles F. Kettering Prize, General Motors Cancer Research Foundation
1999	Centeon Award, 6th International Conference on Bispecific Antibodies
2000	C. Chester Stock Award, Memorial Sloan-Kettering Cancer Center
2000	Medal of Honor, American Cancer Society
2000	Key to the Cure Award, Cure for Lymphoma Foundation
2001	Evelyn Hoffman Memorial Award, Lymphoma Research Foundation of America
2003	Jeffrey A. Gottlieb Memorial Award, M.D. Anderson Cancer Center

Professional Review Activities

1988 – 1992	Chairman, American Cancer Society Immunology Study Section
1989 – 1993	Chairman, Board of Scientific Counselors, Division of Cancer Treatment, National Institute of Health
1992 - 1996	Program Committee and Block Chairman for Tumor Immunology, American Association of Immunology
1992 - 1996 and 2001 - present 1994 - present	General Motors Cancer Research Foundation Awards Assembly Scientific Advisory Board, Fred Hutchinson Cancer Research Center
2001	American Association of Medical Schools Task Force on Financial Conflicts of Interest in Clinical Research
2002 - present 2001	Board of Directors, Damon Runyon Cancer Research Fund Dorothy P. Landon - American Association for Cancer Research Translational Cancer Research Prize Committee
2001 - present	Conflict of Interest Committee for Stanford University School of Medicine
2002	Chairman, Joseph H. Burchinal Award Committee, American Association of Cancer Research
2003 - present	Member Research Council, American Cancer Society

Research Grant Committees

Margaret Early Trust
G&P Charitable Foundation Award
The V Foundation Award
Damon Runyon Clinical Investigators Award
Lymphoma Research Foundation

Scientific Advisory Boards

XTL Therapeutics, Rehovoth, Israel
Therion Incorporated, Cambridge, MA
Coley Pharmaceutical Group Inc. New York, NY
Xcyte Therapeutics, Seattle, WA
Agensys, Santa Monica, CA
Pointilliste, Mountain View, CA
Cell Genesis, Foster City, CA
Five Prime, South San Francisco, CA

Society Memberships

American College of Physicians
American Association for Cancer Research
American Society of Clinical Oncology
American Association of Immunology
American Federation for Clinical Research
American Society of Clinical Investigation
American Society of Hematology
Western Society of Medicine
Association of American Physicians
Academy of Cancer Immunology

MAJOR RESEARCH INTERESTS

Immunology, Cancer Biology, Medical Oncology

VISITING PROFESSORSHIPS

1994	Woodward Visiting Professor, Memorial Sloan Kettering Cancer Center, NY
1995	Morton Mason Lecture, University of Texas Southwestern
1996	University of Minnesota Cancer Center
1999	University of Nebraska Cancer Center

INVITED LECTURESHIPS (last 4 years)

January 2000	DNA Microarray Analysis of Lymphoma. 2 nd Annual Northwestern University Medical School Oncology Consensus Conference, Kailua-Kona, HI
January 2000	Antigen Receptors as Targets for Therapy of Lymphoma. Keystone Symposium on Molecular and Cellular Biology, Santa Fe, NM
March 2000	Host/Tumor Cell Interaction. Lymphoma Think Tank, Lymphoma Research Foundation of America, Atlanta GA
March 2000	Critical Issues of Cell-Based Vaccines and their Clinical Translation. Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy, Albert B. Sabin Vaccine Institute, Bahamas
April 2000	Tumor Vaccines. Annual Meeting of the American Association for Cancer Research, San Francisco, CA
April 2000	Immune Therapy. Innovation in Lymphoma Research and Management, Memorial Sloan-Kettering Cancer Center, New York, NY.
April 2000	The Development of Monoclonal Antibodies and Vaccines for the Treatment of Lymphoma. Gerhard Schmidt Memorial Lecture, City of Hope National Medical Center, Duarte, CA
May 2000	From Fundamental Discovery to New Therapy: Monoclonal Antibodies as a Case Study. C. Chester Stock Award Lecture, Memorial Sloan-Kettering Cancer Center, New York, NY
June 2000	Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Progenitor-Cell Transplantation for Multiple

Myeloma. Experts Roundtable on Immune Therapy, Multiple Myeloma Research Foundation, McLean, VA

July 2000 Immunotherapy of Lymphoma. Bagshawe Lecture, British Cancer Research Meeting, University of Sussex, Brighton, UK

September 2000 Clone Specific Targeting of Malignant Lymphomas. Basic and Clinically Relevant Biology of Cutaneous T Cell Lymphoma, New York Academy of Sciences/Yale University School of Medicine, New York, NY

September 2000 Keynote address. Rituxan Clinical Investigators Meeting, Washington, DC

September 2000 BLyS and BLyS Receptor Levels in non-Hodgkin's Lymphoma. Human Genome Sciences BLyS Experts Advisory Panel Meeting, Rockville, MD

October 2000 Immunotherapy of Lymphoma. Frontiers in Cancer Cytotherapy, Frisbee Foundation Stem Cell Symposium, Yale Cancer Center, New Haven, CT

December 2000 Immunotherapy of Lymphoma. New Horizons in Immunotherapy of Leukemia and Lymphoma, Leukemia & Lymphoma Society Symposium at the American Society of Hematology Annual Meeting, San Francisco, CA

December 2000 Monoclonal Antibodies for the Treatment of Lymphoma: Many Different Ways to Use a New Modality. American Society of Hematology Annual Meeting, San Francisco, CA

January 2001 DNA Microarray Analysis for Classification of Lymphomas. Third Annual Oncology Opinion Leader Roundtable, Northwestern University Medical School, Kailua-Kona, HI

January 2001 Immunotherapy of Lymphoma. American Cancer Society California Division Board of Directors Annual Meeting, Oakland, CA

February 2001 Vaccine Therapy for the Treatment of Lymphoma. Hedda V. Green Memorial Lecture, Cedars-Sinai Medical Center, Los Angeles, CA

March 2001 Lymphoma Tumor Board, Northern California Tumor Board at Silverado, Napa, CA

March 2001 Therapy of Human Lymphoma. Keystone Symposium on Recent Advances in the Pathogenesis and Treatment of Leukemia and Lymphoma. Keystone, CO

April 2001	Monoclonal Antibodies and Vaccines in the Treatment of Lymphoma. Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
April 2001	Lymphoma Vaccines. Celera Genomics, Rockville, MD.
June 2001	Immunologic Approaches to the Treatment of Cancer. Johns Hopkins Oncology Center, Baltimore, MD.
June 2001	Update on Vaccine Therapy for Follicular Non-Hodgkin's Lymphoma. Pan Pacific Lymphoma Conference, Maui, HI
March 2002	Lymphoma Tumor Board, Northern California Tumor Board at Silverado, Napa, CA
March 2002	American Cancer Society Foundation, Las Vegas, NV
April 2002	Immunotherapy. American Association for Cancer Research Annual Meeting, San Francisco, CA
April 2002	Lymphoma: New Pathways to a Cure. Community Hospital Foundation, Monterey, CA
May 2002	Genentech Research Conference, Asilomar, Monterey, CA
May 2002	Antigenics Satellite Symposium on "Cancer Vaccines: Recent Advances" at ASCO Annual Meeting, Orlando, Florida
June 2002	8 th International Conference on Malignant Lymphoma, Lugano, Switzerland
June/July 2002	FOCIS 2 nd Annual Meeting, San Francisco, CA
September 2002	Cancer Research Symposium, University of California, Davis, CA
November 2002	Systemics 2002: Integrating Proteomics, Genomics and Metabonomics. San Francisco, CA
November 2002	Northern California Division's Scientific Symposium, Children's Hospital, Oakland, CA
January 2003	Workshop on Lymphoid Malignancies, Palm Beach, Florida
February 2003	Lymphoma Society Focus Group Workshop, Miami, Florida
February 2003	Symposium on Basic Aspects of Tumor Immunology, Keystone, Colorado
March 2003	Symposium on Molecular Medicine, La Jolla, California

PUBLICATIONS

1. Fulco AJ, Levy R and Block K: The biosynthesis of 9 and 5 monosaturated fatty acids by bacteria. **J Biol Chem** 239:998–1003, 1964.
2. McKhann GM, Levy R and Ho W: Metabolism of sulfatides. I. The effect of galactocerebrosides on the synthesis of sulfatides. **Biochem and Biophys Res Comm** 20:109–113, 1965.
3. Stossel TP and Levy R: Intravascular coagulation associated with pneumococcal bacteremia and symmetrical peripheral gangrene. **Arch Intern Med** 125:876–878, 1970.

1972

4. Levy R and Rosenberg SA: The early stimulation of protein synthesis in sensitized guinea pig lymph node cells by antigen. **J Immunol** 108:1073–1079, 1972.
5. Rosenberg SA and Levy R: A rapid assay of cell mediated immunity to soluble antigens based on the stimulation of protein synthesis. **J Immunol** 109:1080, 1972.
6. Rosenberg SA, Levy R, Schechter B, Ficker S and Terry WD: A rapid microassay of cellular immunity in the guinea pig and mouse. **Transplantation** 13:541–545, 1972.
7. Rosenberg SA and Levy R: Synthesis of nuclear-associated proteins by lymphocytes within minutes after contact with phytohemagglutinin. **J Immunol** 108:1105–1109, 1972.

1973

8. Levy R and Rosenberg SA: Protein synthesized in lymphoid cells early after activation by phytohemagglutinin. **Cell Immunol** 7:92–107, 1973.
9. Levy R, Levy S, Rosenberg SA and Simpson RT: Selective stimulation of nonhistone chromatin protein synthesis in lymphoid cells by phytohemagglutinin. **Biochemistry** 12:224–228, 1973.
10. Schechter B, Rosenberg SA, Levy R, Ficker S and Terry W: Early evaluation of mixed leukocyte interaction in mice and guinea pigs using measurements of protein synthesis. **Cell Immunol** 6:261–272, 1973.

1974

11. Levy R, Hurwitz E, Maron R, Arnon R and Sela M: The specific cytotoxic effects of daunomycin conjugated to anti-tumor antibodies. **Cancer Res** 35:1182–1186, 1975.

1976

- Gabbay EJ, Grier D, Fingerle RE, Reimer R, Levy R, Pearce SW and Wilson WD: Interaction specificity of the anthracyclines with DNA. **Biochemistry** 15:2062–2070, 1976.

1977

- Levy R, Warnke R, Dorfman RF and Haimovich J: The monoclonality of human B cell lymphomas. **J Exp Med** 145:1014–1027, 1977.
- Levy R and Dilley J: The in vitro antibody response to cell surface antigens. I. The xenogeneic response to human leukemia cells. **J Immunol** 119:387–393, 1977.
- Levy R and Dilley J: The in vitro antibody response to cell surface antigens. II. Monoclonal antibodies to human leukemia cells. **J Immunol** 119:394–400, 1977.
- Lampson LA, Royston I and Levy R: Homogeneous antibodies directed against human cell surface antigens. I. The mouse spleen fragment culture response to T and B cell lines derived from the same individual. **J Supramolecular Struct** 6:441–448, 1977.

1978

- Lampson LA, Levy R, Grumet FC, Ness D and Pious D: Production in vitro of murine antibody to a human histocompatibility alloantigen. **Nature** 271:461–462, 1978.
- Warnke R and Levy R: Immunopathology of follicular lymphomas. A model of B lymphocyte homing. **New Eng J Med** 298:481–486, 1978.
- Levy R and Dilley J: Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. **Proc Natl Acad Sci** 75:2411–2415, 1978.
- Kadin ME, Stites DP, Levy R and Warnke R: Exogenous immunoglobulin and the macrophage origin of Reed-Sternberg cells in Hodgkin's disease. **New Eng J Med** 299:1208–1214, 1978.
- Epstein AL, Levy R, Kin H, Henle W, Henle G and Kaplan HS: Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. **Cancer** 42:2379–2391, 1978.
- Warnke R, Pederson M, Williams C and Levy R: A study of lymphoproliferative diseases comparing immunofluorescence with immunohistochemistry. **Amer J Clin Path** 70:867–875, 1978.
- Merigan TC, Sikora K, Breeden JH, Levy R and Rosenberg SA: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. **New Eng J Med** 299:1449–1453, 1978.

1979

- Lampson LA and Levy R: A role for clonal antigens in cancer diagnosis and therapy. **J Natl Cancer Inst** 62:217–219, 1979.

25. Sikora K, Krikorian J and Levy R: Monoclonal immunoglobulin rescue from a patient with chronic lymphocyte leukemia and autoimmune hemolytic anemia. **Blood** 54: 513–517, 1979.
26. Levy R, Dilley J, Fox RI and Warnke R: A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies. **Proc Natl Acad Sci** 76:6552–6556, 1979.

1980

27. Lampson LA and Levy R: Two populations of Ia-like molecules on human B cell line. **J Immunol** 125:293–299, 1980.
28. Warnke R, Miller R, Grogan T, Pederson M, Dilley J and Levy R: Immunologic phenotype in 30 patients with diffuse large cell lymphoma. **New Eng J Med** 303: 293–300, 1980.
29. Brown S, Dilley J and Levy R: Immunoglobulin secretion by mouse x human hybridomas. An approach for the production of anti-idiotypic reagents useful in monitoring patients with B cell lymphoma. **J Immunol** 125:1037–1043, 1980.
30. Warnke R and Levy R: Detection of T and B cell antigens with hybridoma monoclonal antibodies. A biotin-avidin-horseradish peroxidase method. **J Histochem and Cytochem** 28:771–776, 1980.
31. Rich RR, Abramson SL, Seldin MF, Puck JM and Levy R: Role of Ia-positive cells in induction of secondary human immune responses to Haptens in vitro. **J Exp Med** 152(2):218S–234S, 1980.
32. Sikora K, Dilley J, Basham T, Levy R and Merigan T: Inhibition of lymphoma hybrids by human interferon. **The Lancet**, 891–893, October 25, 1980.
33. Goodfellow P, Banting F, Levy R, Povey S and McMichael A: A human x-linked antigen defined by a monoclonal antibody. **Somatic Cell Genetics** 6:777–787, 1980.
34. Grumet FC, Charron DJ, Fendly BM, Levy R and Ness DB: HLA-DR epitope region definition by use of monoclonal antibody probes. **J Immunol** 125:2785–2789, 1980.

1981

35. Engleman EG, Warnke R, Fox RI, Dilley J, Benike CJ and Levy R: Studies of a human T lymphocyte antigen recognized by a monoclonal antibody. **Proc Natl Acad Sci** 78:1791–1795, 1981.
36. Zipf TF, Fox RI, Dilley J and Levy R: Definition of the high risk acute lymphoblastic leukemia patient by immunological phenotyping with monoclonal antibodies. **Cancer Research** 41:4786–4789, 1981.

37. Hatzubai A, Maloney DG and Levy R: The use of a monoclonal anti-idiotypic antibody to study the biology of a human B cell lymphoma. **J Immunol** 126:2397–2402, 1981.
38. Miller RA, Maloney DG, McKillop J and Levy R: In vivo effects of murine hybridoma monoclonal antibody in a patient with T cell leukemia. **Blood** 58:78–86, 1981.
39. Miller RA and Levy R: Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. **The Lancet**, 226–229, August 1, 1981.
40. Neubauer RH, Levy R, Strnad BC and Rabin H: Reactivity of monoclonal antibodies against human leucocyte antigens with lymphocytes of non-human primate origin. **J Immunogenetics** 8:433–442, 1981.
41. Louie AC, Gallagher JG, Sikora K, Levy R, Rosenberg SA and Merigan TC: Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. **Blood** 58:712–718, 1981.
42. Levy R, Bergman Y and Finn OJ: Hybridoma monoclonal antibodies in the analysis of human cell surface antigens. **In Vitro** 17:1051–1057, 1981.

1982

43. Bergman Y and Levy R: Biosynthesis and processing of a human T lymphocyte antigen. **J Immunol** 128:1334–1340, 1982.
44. Wood GS, Deneau DG, Miller RA, Levy R, Hoppe RT and Warnke RA: Sub-types of cutaneous T cell lymphoma defined by expression of Leu-1 and Ia. **Blood** 59:876–882, 1982.
45. Miller RA, Maloney DG, Warnke R and Levy R: Treatment of B cell lymphoma with monoclonal anti-idiotypic antibody. **New Eng J Med** 306:517–522, 1982.
46. Finn OJ and Levy R: Multiple HLA-DR antigens: Detection with monoclonal antibodies and translation *in vitro*. **Proc Natl. Acad Sci** 79:2658–2662, 1982.
47. Dvoretzky P, Wood GS, Levy R and Warnke RA: T lymphocyte subsets in follicular lymphomas compared to those in non-neoplastic lymph nodes and tonsils. **Human Path** 13:618–625, 1982.
48. Hurley CK, Nunez G, Winchester R, Finn OJ, Levy R and Capra, JD: The human HLA-DR antigens are encoded by multiple beta-chain loci. **J Immunol** 129:2103–2108, 1982.
49. Stratte PT, Miller RA, Amyx HL, Asher DM and Levy R: In vivo effects of murine monoclonal anti-human T cell antibodies in subhuman primates. **J Biol Response Modifiers** 1:137–148, 1982.
50. Kaizer H, Levy R, Brovall C, Civin CI, Fuller DJ, Hsu SH, Leventhal BG, Miller RA, Milvenan ES, Santos GW and Wharam MD: Autologous bone marrow transplantation in T cell malignancies: A case report involving *in vitro* treatment of marrow with a Pan-T cell monoclonal antibody. **J Biol Resp Mod** 1:233–243, 1982.

1983

51. Levy R and Miller RA: Tumor therapy with monoclonal antibodies. **Federation Proceedings** 42:2650–2656, 1983.
52. Link MP, Roper M, Dorfman RF, Crist WM, Cooper MD and Levy R: Cutaneous lymphoblastic lymphoma with pre-B markers. **Blood** 61:838–841, 1983.
53. Bergman Y, Stewart SJ, Levy S and Levy R: Biosynthesis, glycosylation and in vitro translation of the human T cell antigen Leu-4. **J Immunol** 131:1876–1881, 1983.
54. Fujimoto J, Levy S and Levy R: Spontaneous release of the Leu-2 (T8) molecule from human T cells. **J Exp Med** 159:752–766, 1983.
55. Link M, Warnke R, Finlay J, Amylon M, Miller R, Dilley J and Levy R: A single monoclonal antibody identified T cell lineage of childhood lymphoid malignancies. **Blood** 62:722–728, 1983.
56. Miller RA, Oseroff AR, Stratte PT and Levy R. Monoclonal antibody therapeutic trials in seven patients with T cell lymphoma. **Blood** 62:988–995, 1983.
57. Wood GS, Burke JS, Horning S, Doggett RS, Levy R and Warnke RA: The immunologic and clinicopathologic heterogeneity of cutaneous lymphomas other than mycosis fungoides. **Blood** 62:464–472, 1983.

1984

58. Wood GS, Link M, Warnke RA, Dilley J and Levy R: Pan-leukocyte monoclonal antibody L3B12: Characterization and application to research and diagnostic problems. **Amer J Clin Path** 81:176–183, 1984.
59. Sklar J, Cleary ML, Thielemans K, Gralow J, Warnke R and Levy R: Biclinal B cell lymphoma. **New Eng J Med** 311:20–27, 1984.
60. Thielemans K, Maloney DG, Meeker T, Fujimoto JH, Doss C, Gralow J, Miller RA and Levy R: Strategies for production of monoclonal anti-idiotypic antibodies against human B cell lymphomas. **J Immunol** 133:495–501, 1984.
61. Fujimoto J, Stewart SJ and Levy R: Immunochemical analysis of the released Leu-2 (T8) molecule. **J Exp Med** 160:116–124, 1984.
62. Berenson RJ, Levitt LJ, Levy R and Miller RA: Cellular immunoabsorption using monoclonal antibodies: Selective removal of T cells from peripheral blood and bone marrow. **Transplantation** 38:136–143, 1984.
63. Doggett RS, Wood GS, Horning SJ, Levy R, Dorfman RF, Bindl J and Warnke RA: The immunological characterization of 95 nodal and extranodal large cell lymphomas in 89 patients. **Amer J Path** 115:245–252, 1984.

64. Horning SJ, Doggett RS, Warnke RA, Dorfman RF, Cox RS and Levy R: Clinical relevance of immunologic phenotype in diffuse large cell lymphoma. **Blood** 63: 1209–1215, 1984.
65. Meeker TC, Miller RA, Link MP, Bindl J, Warnke R and Levy R: A unique human B lymphocyte antigen defined by a monoclonal antibody. **Hybridoma** 3:305–320, 1984.

1985

66. Meeker TC, Lowder JN, Maloney DG, Miller RA, Thielemans K, Warnke R and Levy R: A clinical trial of anti-idiotypic therapy for B cell malignancy. **Blood** 65:1349–1363, 1985.
67. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J and Levy R: Emergence of idiotype variants during therapy of B cell lymphoma with anti-idiotypic antibodies. **New Eng J Med** 312:1658–1665, 1985.
68. Link MP, Stewart SJ, Warnke RA and Levy R: Discordance between surface and cytoplasmic expression of the Leu-4 (T3) antigen in thymocytes and in blast cells from childhood T-lymphoblastic malignancies. **J Clin Invest** 76:248–253, 1985.
69. Thompson JM, Gralow JR, Levy R and Miller RA: The optimal application of forward and ninety-degree light scatter in flow cytometry for the gating of mononuclear cells. **Cytometry** 6:401–406, 1985.
70. Thielemans K, Rothbard JB, Levy S and Levy R: Syngeneic anti-idiotypic immune responses to a B cell lymphoma. Comparison between V_H hypervariable region peptides and intact immunoglobulin as immunogens. **J Exp Med** 162:19–34, 1985.
71. Garcia CF, Lowder J, Meeker TC, Bindl J, Levy R and Warnke RA: Differences in host infiltrates among lymphoma patients treated with anti-idiotypic antibodies: Correlation with treatment response. **J Immunol** 135:4252–4260, 1985.
72. Vaickus L and Levy R: Anti-proliferative monoclonal antibodies: Detection and initial characterization. **J Immunol** 135:1987–1997, 1985.
73. Maloney DG, Kaminski MS, Burowski D, Haimovich J and Levy R: Monoclonal anti-idiotypic antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumor in vivo and in vitro. **Hybridoma** 4:191–209, 1985.
74. Liu MA, Kranz DM, Kurnick JT, Boyle LA, Levy R and Eisen HN: Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. **Proc Natl Acad Sci** 82:8648–8653, 1985.
75. Hu E, Thompson J, Lowder JN, Horning S, Levy R and Sklar J: B lymphoma in peripheral blood detected by DNA hybridization. **The Lancet**, 1092–1095, November 16, 1985.

1986

76. Kaminski MS, Kitamura K, Maloney DG and Levy R: Importance of antibody isotype in monoclonal anti-idiotypic therapy of a murine B cell lymphoma: A study of hybridoma class switch variants. **J Immunol** 36:1123–1130, 1986.
77. Carroll WL, Thielemans K, Dilley J and Levy R: Mouse x human heterohybridomas as fusion partners with human B cell tumors. **J Immunol Methods** 89:61–72, 1986.
78. Cleary ML, Meeker TC, Levy S, Lee B, Trela M, Sklar J and Levy R: Clustering of extensive somatic mutations in the immunoglobulin heavy chain variable region gene of a human B cell lymphoma. **Cell** 44:97–106, 1986.
79. Campbell ML, Bieber M, Levy R and Teng NHH: Influence of avidity and idiotope recognition on the modulation of surface immunoglobulin on malignant human B cells by rat monoclonal anti-idiotypic antibodies. **J Immunol** 36:2983–2988, 1986.
80. Stewart S, Fujimoto J and Levy R: Human T lymphocytes and monocytes bear the same Leu-3(T4) antigen. **J Immunol** 136:3773–3778, 1986.
81. Link M, Bindl J, Meeker T, Carswell C, Doss C, Warnke R and Levy R: A unique antigen on mature B cell defined by a monoclonal antibody. **J Immunol** 137: 3013–3018, 1986.
82. Basham T, Kaminski MS, Kitamura K, Levy R and Merigan TC: Synergistic antitumor effect of interferon and anti-idiotypic monoclonal antibody in murine lymphoma. **J Immunol** 137:3019–3024.
83. Carroll WL, Lowder JN, Streifer R, Warnke R., Levy S and Levy R: Idiotype variant cell populations in patients with B cell lymphoma. **J Exp Med** 164:1566–1580, 1986.

1987

84. Lowder J, Meeker T, Campbell M, Garcia C, Gralow J, Miller R, Warnke R and Levy R: Studies on B lymphoid tumors treated with monoclonal anti-idiotypic antibodies. Correlation with clinical responses. **Blood** 69:199–210, 1987.
85. Lowder JN, Miller RA, Hoppe R and Levy R: Suppression of anti-mouse immunoglobulin antibodies in primates receiving murine monoclonal antibodies against T cell antigens. **J Immunol** 138:401–406, 1987.
86. Kaminski MS, Kitamura K, Maloney DG and Levy R: Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. **J Immunol** 138:1289–1296, 1987.
87. Garcia CF, Weiss LM, Lowder J, Komorose C, Link MP, Levy R and Warnke RA: Quantitation and estimation of lymphocyte subsets in tissue sections: Comparison with flow cytometry. **Amer J Clin Path** 87:470–477, 1987.

88. Miller RA, Lowder JN, Gralow J, Meeker T and Levy R: In vitro tests which predict tumor-associated idiotype levels in the serum of patients with B cell lymphomas and leukemias. **Blood** 69:1249–1254, 1987.
89. Kon S, Levy S and Levy R: Retention of an idiotypic determinant in a human B-cell lymphoma undergoing immunoglobulin variable-region mutation. **Proc Natl Acad Sci USA** 84:5053–5057, 1987.
90. Maecker HT, Kitamura K, Brenner MB and Levy R: Isolation of anti-idiotypic antibodies to T cells using an anti-framework determinant antibody. **J Immunol Methods** 98:219, 1987.
91. Berinstein N and Levy R: Treatment of a murine B cell lymphoma with monoclonal antibodies and IL2. **J Immunol** 139:971–976, 1987.
92. Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S and Levy R: Idiotype vaccination against murine B cell lymphoma: Humoral and cellular responses elicited by tumor-derived IgM and its molecular subunits. **J Immunol** 139:2825–2833, 1987.
93. Berinstein N, Matthay KK, Papajadjopoulos D, Levy R and Sikic B: Antibody-directed targeting of liposomes to human cell lines: Role of binding and internalization on growth inhibition. **Cancer Research** 47:5954–5959, 1987.
94. Levy S, Kon S and Levy R: Somatic mutations in the Ig V_H genes of human B cell lymphoma. **Acta Paediatr Jpn** 29:561-565, 1987.

1988

95. Carroll WL, Link MP, Cleary ML, Bologna S, Carswell CC, Amylon MD, Smith SD and Levy R: Idiotype as a tumor specific marker in childhood B cell acute lymphoblastic leukemia. **Blood** 71:1068–1073, 1988.
96. Berinstein N, Starnes CO and Levy R: Specific enhancement of the therapeutic effect of anti-idiotypic antibodies on a murine B cell lymphoma by Interleukin 2. **J Immunol** 140:2839–2845, 1988.
97. Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G and Levy R: Heterogeneity of a murine B cell lymphoma: Isolation and characterization of idiotypic variants. **J Immunol** 141:333–339, 1988.
98. Cleary ML, Galili N, Trela M, Levy R and Sklar J: Single cell origin of bi-genotypic and bi-phenotypic B-cell proliferations in human follicular lymphomas. **J Exp Med** 167:582–599, 1988.
99. Levy S, Mendel E, Kon S, Avnur Z and Levy R: Mutational hot-spots in immunoglobulin region genes of human follicular lymphomas. **J Exp Med** 168:475–489, 1988.
100. Basham TY, Palladino MA, Badger CC, Bernstein ID, Levy R and Merigan TC: Comparison of combinations of interferons with tumor specific and non-specific monoclonal antibodies as therapy for murine B and T cell lymphomas. **Cancer Research** 48:4196–4200, 1988.

101. Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, and Merigan TC: Synergistic antitumor activity with IFN and monoclonal anti-idiotypic for murine B cell lymphoma. Mechanism of action. **J Immunol** 141:2855–2860, 1988.
102. Maecker H and Levy R: Spontaneous T cell antigen receptor variants of a human T leukemia cell line. **J Immunol** 141:2994–3002, 1988.
103. Campbell MJ, Esserman L and Levy R: Immunotherapy of established murine B cell lymphoma. **J Immunol**. 141:3227–3233, 1988.
104. Carroll WL, Starnes CO, Levy R and Levy S: Alternative V_K gene rearrangements in a murine B cell lymphoma. An explanation for idiotypic heterogeneity. **J Exp Med** 168:1607–1620, 1988.

1989

105. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC and Levy R: Treatment of B cell lymphoma with anti-idiotypic antibodies alone and in combination with alpha interferon. **Blood** 73:651–661, 1989.
106. Maecker H and Levy R: Prevalence of antigen receptor variants in human T cell lines and tumors. **J Immunol** 142:1395–1404, 1989
107. Berinstein N, Levy S and Levy R: Activation of an excluded immunoglobulin allele in a human B lymphoma cell line. **Science** 244:337–339, 1989.
108. Wright A, Clayberger C, Link MP, Smith SD, Levy R, Brenner MB and Krensky AM Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor d chain. **J Exp Med** 169:1557–1564, 1989.
109. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSantes K, Porter B, Kidd P, Thomas ED and Bernstein I. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. **J Clin Oncol** 7:1027–1038, 1989.
110. Levy S, Campbell MJ and Levy R: Functional immunoglobulin light chain genes are replaced by ongoing rearrangements of germline V_K genes to downstream J_K segments in a murine B cell line. **J Exp Med** 170:1–13, 1989.
111. Miller RA, Hart S, Samouszuk M, Coulter C, Kelkernberg J, Brown S, Czerwinski D, Royston I and Levy R: Shared idiotypes expressed by human B cell lymphomas. **New Eng J Med** 321:851–857, 1989.
112. Esserman L, Takahashi S, Rojas V, Warnke R and Levy R: An epitope of the transferrin receptor is exposed on the cell surface of high grade but not low grade human lymphomas. **Blood** 74:2718–2729, 1989.

113. Takahashi S, Maecker H T, and Levy, R. DNA fragmentation and cell death mediated by T cell antigen receptor/CD3 complex on a leukemia T cell line. **Eur. J. Immunol** 19: 1911–1919, 1989.

1990

114. Berinstein N, Campbell MJ, Lam K, Carswell C, Levy S and Levy R: Idiotypic variation in human B lymphoma cell line. **J Immunol** 144:752–758, 1990.
115. Umetsu, D. T., Esserman, L., Donlan, T. A., DeKruyff, R. H., and Levy, R. Induction of proliferation of human follicular (B-type) lymphoma cells by cognate interaction with a CD4+ T cell clone. **J. Immunol** 144: 2550–2557, 1990.
116. Zelenetz A and Levy R: Directional cloning of cDNA using a selectable Sfi I cassette. **Gene** 89:123–127, 1990
117. Oren R, Takahashi S, Doss C, Levy R and Levy S: TAPA-1, the target of an anti-proliferative antibody defines a new family of transmembrane proteins. **Mol Cell Bio** 10:4007–4015, 1990.
118. Knox, S. J., Levy, R., Miller, R. A., Umland, W., Schiele, J., Ruehl, W., Finston, R., Day-Lollini, P., and Goris, M. L. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. **Cancer Res** 50: 4935–4940, 1990.
119. Kwak LW, Campbell MJ, Zelenetz AD, and Levy R: Combined syngeneic bone marrow transplantation and immunotherapy of a murine B cell lymphoma: Active immunization with tumor-derived idiotypic IgM . **Blood** 76:2411–2417, 1990.
120. Takahashi S, Doss C, Levy S, and Levy R. TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. **J. Immunol** 145:2207–2213, 1990.

1991

121. Zelenetz A D, Chen TT, and Levy, R. Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell. **J. Exp. Med** 173:197–207, 1991.
122. Takahashi S, L Esserman, and Levy, R. An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site. **Blood** 77:826–832, 1991.
123. Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S, Chen TT, Andria ML, Levy S, Miller RA, and Levy R. Follicular lymphoma: A model of lymphoid tumor progression in man. **Annals of Oncology** 2:115–122, 1991.
124. Knox SJ, Levy R, Hodgkinson S, Bell R, Brown S, Wood GS, Hoppe R, Abel E A, Steinman L, Gaiser C , Young G , Bindl J , Hanham A, and Reichert T. Observations on the effect of Chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. **Blood** 77:20–30, 1991.

125. Berger RG, Knox SJ, Levy R, Sklar JL, Cohen P, and Reichert T. Mycosis Fungoides Arthropathy. **Annals of Internal Med** 114:571–572, 1991.
126. Stewart SJ and Levy R: Components of the human T lymphocyte antigen receptor complex, CD3-p28 and CD3-gamma, are biochemically distinct. **J Laboratory and Clinical Medicine** 114:394–400, 1991.
127. Eary J, Press O, Badger C, Durack L, Richter K, Addison S, Krohn K, Fisher D, Porter B, Williams D, Martin P, Appelbaum F, Levy R, Brown S, Miller R, Nelp W and Bernstein I: Imaging and treatment of B-cell lymphoma. **J Nuclear Med** 31: 1257–1268, 1991.
128. Dighiero G, Hart S, Lim A, Borch L, Levy R, and Miller RA: Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. **Blood** 78:581–585, 1991.
129. Kwak LW, Campbell MJ, Zelenetz AD and Levy R: Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: A strategy for using autologous marrow as an anti-tumor therapy. **Blood** 78:2768–2772, 1991.
130. Zelenetz AD, Chu G, Galilli N, Bangs CD, Horning S J, Donlon TA, Cleary ML, and Levy R. 1991. Enhanced detection of the t(14; 18)translocation in malignant lymphoma using pulsed-field gel electrophoresis. **Blood** 78:1552–1560, 1991.
131. Bahler DW, Campbell M J, Hart S, Miller R, Levy S, and Levy R: Ig VH gene expression among human follicular lymphomas. **Blood** 78:1561–1568, 1991.

1992

132. Campbell MJ, Zelenetz A D, Levy S, and Levy S. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. **Molec Imm** 29:193–203, 1992.
133. Bahler DW, Gerry G, Oksenberg J, Warnke RA, and Levy R. Diversity of T cell antigen receptor variable genes used by mycosis fungoides cells. **Am J Path** 140:1–8, 1992.
134. Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Campbell M, Levy R and Krensky AM. Interleukin 3 is a growth factor for human follicular B cell lymphoma. **J Exp Med** 175:371–376, 1992.
135. Bahler DW and Levy R. Clonal evolution of a follicular lymphoma: Evidence for antigen selection. **Proc Natl Acad Sci** 89:6770–6774, 1992.
136. Zelenetz AD, Chen TT, and Levy R. Clonal Expansion in follicular lymphoma occurs subsequent to antigenic selection. **J Exp Med** 176:1137–1148, 1992.
137. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, and Levy R. Induction of immune responses in patients with B cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. **N Eng J Med** 327: 1209–1215, 1992.

138. Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, and Levy R. Monoclonal anti-idiotypic antibody therapy of B cell lymphoma: The addition of a short course of chemotherapy does not prevent the emergence of idiotype negative variant cells. **Blood** 80:1502–1510, 1992.
139. Kwak LW, Campbell MJ, and Levy R. Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by Interleukin-2: A model for the graft versus leukemia reaction. **Cancer Research** 52:4117–4120, 1992.

1993

140. Zelenetz AD, Cleary ML and Levy R. An interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14; 18) translocation breakpoint in human follicular lymphoma . **Genes, Chromosomes and Cancer** 6:1–11, 1993.
141. Tao M-H and Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. **Nature** 362: 755–758, 1993.
142. Wood GS, Bahler DW, Hoppe RT, Warnke RA, Sklar JL and Levy R. Transformation of mycosis fungoides: T-cell receptor b gene analysis demonstrates a common clonal origin for plaque-type mycosis fungoides and CD30⁺ large cell lymphoma. **J Investigative Derm** 101 (3):296–300, 1993.
143. Hsu F, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R. Clinical trials of idiotype-specific vaccine in B-cell lymphomas. **Annals of the NY Acad of Sci** 690:385–7, 1993.

1994

144. Renschler WF, Bhatt RR, Dower WJ and Levy R. Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. **Proc of the Nat Acad of Sci** 91(9):3623–7, 1994.
145. Vuist W, Maloney D, and Levy R. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce immunoglobulins signal transduction and is not prevented by tumor expression of high levels of Bcl-2 protein. **Blood**. Vol 83(4):899–906, 1994.
146. Maloney D, Liles T, Czerwinski D, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. **Blood** 84(8):2457–2466, 1994.
147. Chen T, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. **J Immuno** 153:4775–4787, 1994.

1995

148. Chen T, Levy R. Induction of autoantibody responses to GMCSF by hyperimmunization with an idiotype-GMCSF fusion protein. **J Immuno** 154:3105–3117, 1995.
149. Hsu F, Levy R. Preferential use of the VH4 immunoglobulin gene family by diffuse large cell lymphoma. **Blood** 86:3072-3082, 1995.
150. Renschler MF, Wada HG, Fok KS and Levy R. B-Lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification. **Cancer Research** 55: 5642-5647, 1995.
151. Gross G, Levy S, Levy R, Waks T and Eshhar Z. Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumor immunotherapy. **Biochemical Society Transactions** 23:2079-2082, 1995.

1996

152. Knox S, Hoppe R, Maloney D, Gibbs I, Fowler S, Marquez C, Cornbleet PJ, Levy R. Treatment of cutaneous T cell lymphoma with chimeric anti-CD4 monoclonal antibody. **Blood** 87:893-899, 1996.
153. Hsu F, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B cell lymphoma using autologous antigen pulsed dendritic cells. **Nature Medicine** 2:52-58, 1996.
154. Knox S, Goris M, Trisler K, Negrin R, Davis T, Liles TM, Grillo-Lopez A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, and Levy R. Yttrium-90-labeled Anti-CD20 Monoclonal Antibody Therapy of Recurrent B-Cell Lymphoma. **Clinical Cancer Research** 2:457-470, 1996.
155. Nelson E, Li X, Hsu F, Kwak L, Levy R, Clayberger C, Krensky A. Tumor specific, cytotoxic T lymphocyte response after ‘idiotype’ vaccination for B cell, non-Hodgkin’s lymphoma. **Blood** 88:580-589, 1996.
156. Syrengelas A, Chen T and Levy R. DNA Immunization Induces Protective Immunity against B Cell Lymphoma. **Nature Medicine** 2:1038-1041, 1996.
157. Hakim I, Levy S and Levy R. A Nine Amino Acid Peptide from IL-1B Augments Anti Tumor Immune Responses Induced by Protein and DNA Vaccines. **J Immunol**, 157:5503-5511, 1996.

1997

158. Hsu F, Caspar C, Czerwinski D, Kwak L, Liles T, Syrengelas A, Taidi-Laskowski B, and Levy R. Tumor-Specific idiotype vaccines in the treatment of patients with B cell lymphoma-long term results of a clinical trial. **Blood**, 89:3129-3135, 1997.

159. Maloney D, White C, Bodkin D, Liles TM, Royston I, Grillo-Lopez, and Levy R. IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma. *J Clinical Oncology*, 15: 3266-3274, 1997.
160. Maloney D, Grillo-Lopez A, White C, Bodkin D, Schilder R, Neidhart J, Janakiraman N, Foon K, Liles T, Royston I, Davis T, and Levy R. IDEC-C2B8 (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. *Blood*, 90:2188-2195, 1997.
161. Caspar C, Levy S, and Levy R. Idiotype vaccines for non-Hodgkins lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations. *Blood*, 90:3699-3706, 1997.
162. Okada C, Wong C, Denney D. and Levy R. T cell antigen receptor vaccines for active immunotherapy of T cell malignancies. *J Immunol*, 159:5516-5527, 1997.

1998

163. Renschler MF, Dower WJ, and Levy R. Identification of peptide ligands for the antigen binding receptor expressed on Human B-cell lymphomas. *Methods Mol Biol*, 87:209-234, 1998.
164. Haimovich J, Czerwinski D, Wong C, and Levy R. Determination of anti-idiotypic antibodies by surface plasmon resonance. *J Immunol. Methods*, 214:113-119, 1998.
165. McLaughlin P, Grillo-Lopez A, Link B, Levy R, Czuczman M, Williams M, Heyman M, Bence-Bruckler I, White C, Cabanillas F. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program. *J of Clinical Oncology*, 16:2825-2833, 1998.
166. Davis TA, Maloney DG, Czerwinski DK, Liles TM and Levy R. Anti-Idiotypic antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. *Blood*, 92:1184-1190, 1998.
167. McCormick A, Kumagai M, Hanley K, Turpen T, Hakim I, Grill L, Tuse D, Levy S, and Levy R. Rapid Production of specific vaccines for lymphoma by expression of the tumor derived single chain Fv epitopes in tobacco plants. *Proc. Natl. Acad. Sci.*, 96:703-708, 1998.

1999

168. Reichardt V, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, and Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-A feasibility study. *Blood*, 93:2411-2419, 1999.
169. Davis T, Czerwinski D, and Levy R. Therapy of B cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. *Clin Cancer Res*, 5(3):611-615, 1999.

170. Wong C, Okada CY, and Levy R. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response. *J of Immunol*, 162:2251-2258, 1999.
171. Syrengelas A and Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection. *J of Immunol*, 162:4790-4795, 1999.
172. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, and Levy R. Single agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a Phase II trial of Rituximab. *J of Clin Onc*, 17:1851-1857, 1999.
173. Alizadeh A, Eisen M, David RE, Ma C, Sabet H, Tran T, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Chan WC, Greiner T, Weisenburger D, Armitage JO, Lossos I, Levy R, Botstein D, Brown PO, and Staudt LM. The Lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. *Cold Spring Harbor Proc. Symp. Quant. Biol.*, 1999.

2000

174. Lossos I and Levy R. Mutation Analysis of the 5' Noncoding Regulatory Region of the BCL-6 Gene in Non-Hodgkin's Lymphoma: Evidence for Recurrent Mutations and Intraclonal Heterogeneity. *Blood*, 95(4):1400-1405, 2000.
175. Alizadeh A, Eisen M, Davis RE, Ma C, Lossos I, Rosenwald A, Boldrick J, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan W, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*, 403: 503-511, 2000.
176. Lossos, IS, Okada CY, Tibshirani R, Warnke R, Vose JM, Greiner TC, and Levy R. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. *Blood*, 95(5): 1797-1803, 2000.
177. Davis TA, Maloney DG, Grillo-Lopez AJ, White CA, Williams ME, Weiner GJ, Dowden S, and Levy R. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with Rituximab and Interferon Alfa-2A. *Clin. Cancer Research*, 6: 2644-2652, 2000.
178. Timmerman JM and Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. *J. Immunol.* 164(9): 4797-803, 2000.
179. Wong CP and Levy R. Recombinant adenovirus vaccine encoding a chimeric TCR induces protective immunity against a T cell lymphoma. *Cancer Res.* 60(10):2689-95, 2000.
180. Lossos IS and Levy R. Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5' non-coding regulatory region of the BCL-6 gene. *Blood.* 96: 635-639, 2000.

181. Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D, Staudt LM, Levy R. Ongoing immunoglobulin heavy chain somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. *Proc. Nat. Acad. Sciences.* 97: 10209-10213, 2000.
182. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab Anti CD20 Monoclonal antibody therapy in non-Hodgkin's lymphoma: the safety and efficacy of re-treatment. *J. Clin. Onc.* 18(17):3135-43, 2000.
183. Lossos IS, Tibshirani R, Narasimhan B and Levy R. The inference of antigen selection on immunoglobulin genes. *J Immunol* 165: 5122-5126, 2000.
184. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. *Biol Blood Marrow Transplant* 6:621-627, 2000.
185. Hastie T, Tibshirani R, Eisen MB, Alizadeh A, Levy R, Staudt L, Chan WC, Botstein D and Brown P. 'Gene Shaving' as a Method for Identifying Distinct Sets of Genes with Similar Expression Patterns. *GenomeBiology.com*, 1(2), 2000.
186. Lossos IS, Jacobs Y, Cleary ML, Levy R. Re: Akasaka, H., et al., Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. *Cancer Res.*, 60: 2335-2341, 2000.

2001

187. Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD and Levy R. Idiotype-Encoding Recombinant Adenoviruses Provide Protective Immunity against Murine B-Cell Lymphomas. *Blood* 97(5):1370-1377, 2001.
188. Maecker HT, Auffermann-Gretzinger S, Nomura LE, Liso A, Czerwinski DK, Levy R. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. *Clinical Cancer Research* 7: 902s-908s, 2001.
189. Lossos IS, Jones CD, Warnke R, Zehnder JL, Tibshirani R, Levy R. The expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. *Blood* 98: 945-951, 2001.
190. Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. *Leukemia* 15:1451-1457, 2001.
191. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, CD59 on tumor cells does not predict clinical outcome following Rituximab treatment in follicular non-Hodgkin's lymphoma. *Blood* 98(5):1352-1357, 2001.

192. Lossos IS, Jones CD, Zehnder JL, Levy R. A polymorphism in the BCL-6 gene is associated with follicle center lymphoma. *Lymphoma & Leukemia*, 42:1343-1350,2001.
193. Davis TA, Hsu FJ, Caspar CB, van Beckhoven A, Czerwinski DK, Liles T, Taidi B, Benike CJ, Engleman EG, Levy R. Idiotype vaccination following ABMT can stimulate specific anti-idiotypic immune responses in patients with B-cell lymphoma. *Biol Blood Marrow Transplant*, 7:517-522, 2001.

2002

194. Briones J, Timmerman JM, Hilbert DM, Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. *Exp. Hematology*, 30:135-141, 2002.
195. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TA, Engleman EG, Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. *Blood*, 99:1517-1526, 2002.
196. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, Lynch JC, Armitage JO, Warnke RA, Alizadeh AA, Lossos IS, Levy R, Chan WC. The t(14;18) defines a unique subset of diffuse large B cell lymphoma with a germinal center B cell expression profile. *Blood*, 99:2285-2290, 2002.
197. Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, Leong W, Grumet FC, Blume KG, Stockerl-Goldstein KE, Levy R, Shizuru JA. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic transplant recipients. *Blood*, 99:1442-8, 2002.
198. Lossos IS, Alizadeh AA, Diehm M, Warnke R, Thorstenson Y, Oefner PJ, Brown PO, Botstein D, Levy R. Transformation of Follicular Lymphoma to Diffuse Large Cell Lymphoma: Alternative Patterns with Increased or Decreased Expression of *c-myc* and its Regulated genes. *Proceedings of the National Academy of Sciences, Proc Natl Acad Sci U S A*. 99:8886-91, 2002.
199. Briones J, Timmerman JM, Levy R. *In vivo* antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. *Cancer Research*. 62, 3195-99, June 2002.
200. Lossos IS, Thorstenson YR, Wayne TL, Oefner PJ, Levy R, Chu G. Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma. *Leukemia and Lymphoma*. 43, 1079-85, 2002.
201. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, van Beckhoven A, Norman J, and Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric Idiotype in patients with B-Cell lymphoma. *Cancer Research*. 62, 5845-52, 2002.
202. Lossos IS, Natkunam Y, Levy R, Lopez CD. Apoptosis Stimulating Protein of p53 (ASPP2) Expression Differs in Diffuse Large B-Cell and Follicular Center Lymphoma: Correlation With Clinical Outcome. *Leukemia and Lymphoma*. 43, 2309-17, 2002.

203. Lossos IS, Warnke R, Levy R. BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5' regulatory region of the BCL-6 gene. *Leukemia*, 16:1857-62, 2002.

2003

204. Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, and Levy R. *HGAL* is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. *Blood*. 101:433-40, 2003.
205. Bohlen SP, Troyanskaya OG, Alter O, Warnke R, Botstein D, Brown PO, and Levy R. Variation in gene expression patterns in follicular lymphoma and the response to Rituximab. *PNAS*. 100:1926-30, 2003.
206. Martinez-Climent JA, Alizadeh AA, Segraves R, Blesa D, Rubio-Moscardo F, Albertson DG, Garcia-Conde J, Dyer MJS, Levy R, Pinkel D, Lossos IS. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. *Blood*, 101:3109-17, 2003.
207. Briones J, Timmerman JM, Panicalli DL, and Levy R. Antitumor Immunity After Vaccination With B Lymphoma Cells Overexpressing a Triad of Costimulatory Molecules. *JNCI*. 95:548-55, 2003.
208. Lossos IS, Czerwinski, DK, Wechsler, MA, and Levy R. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. *Leukemia*. In press.
209. Do B, Lossos IS, Thorstenson Y, Oefner PJ and Levy R. Analysis of FAS (CD95) Gene Mutations in Higher-Grade Transformation of Follicle Center Lymphoma. *Leukemia & Lymphoma*. In press.
210. Akasaka T, Lossos IS and Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. *Blood*. In press.

BOOK CHAPTERS/REVIEW ARTICLES

1977

1. Klinman NR, Segal GP, Gerhard W, Braciale T and Levy R: Obtaining homogeneous antibody of desired specificity from fragment cultures. **Antibodies in Human Diagnosis and Therapy**. E Haber and RM Krause (eds.), Raven Press, NY, pp. 225–236, 1977.

1978

2. Weissman IL, Warnke R, Butcher EC, Rouse R and Levy R: The lymphoid system: Its normal architecture and the potential for understanding the system through the study of

lymphoproliferative diseases. **Human Pathology**, Volume 9, Number 1, pp. 25–45, January 1978.

3. Kaplan HS and Levy R, eds. **Malignant Lymphoma**. UICC Technical Report Series, Volume 37, Geneva, 239p, 1978.
4. Levy R, Dilley J and Lampson LA: Human normal and leukemia cell surface antigens. Mouse monoclonal antibodies as probes. **Lymphocyte Hybridomas: Current Topics In Microbiology and Immunology**, Volume 81. F Melchers, M Potter and N Warner (eds.), Springer-Verlag, Berlin, pp. 164–169, 1978.
5. Levy R, Dilley J, Siora K and Kucherlapati R. Mouse-human hybridomas. The conversion of non-secreting human B cells into Ig secretors. **Lymphocyte Hybridomas: Current Topics in Microbiology and Immunology**, Volume 81. F Melchers, M Potter and N Warner (eds.), Springer-Verlag, Berlin, pp. 170–172, 1978.

1980

6. Goodenow RS, Brown S, Levy R and Kaplan HS: Partial characterization of the virion proteins of a type-C RNA virus produced by a human histiocytic lymphoma cell line. **Viruses In Naturally Occurring Cancers**. Cold Spring Harbor Conferences on Cell Proliferation, Volume 7, Cold Spring Harbor Laboratory, pp. 737–752, 1980.
7. Levy R, Dilley J, Brown S and Bergman Y: Mouse x human hybridomas. **Monoclonal Antibodies**, Chapter 9. RH Kennett, TJ McKearn and KB Bechtol (eds.), Plenum Publishing Corporation, New York, pp. 137–249, 1980.
8. Warnke R and Levy R: Tissue section immunologic methods in lymphomas. Chapter 12. **Diagnostic Immunohistochemistry**, pp. 203–211, 1980.

1982

9. Levy R, Hatzubai A, Brown S, Maloney D and Dilley J: Immunoglobulin idiotype: A tumor-specific antigen for human B-cell lymphomas. **Malignant Lymphomas**. Chapter 5. Academic Press, Inc., pp. 95–105, 1982.
10. Fox R, Baird S, Kung P, Levy R and Royston I: Cell surface antigens on normal and neoplastic human lymphoid cells. **Human Cancer Markers**. Chapter 2. S Sell and B Wahren (eds.), Humana Press, pp. 33–68, 1982.
11. Miller RA, Stratte PT, Oseroff AR, Link MP and Levy R: Treatment of human T-cell lymphomas and leukemias with monoclonal anti-T cell antibodies. **Hybridomas in Diagnosis and Treatment**. Ortho Pharmaceutical Ltd., Canada, pp. 105–110, 1982.
12. Levy R: Monoclonal antibodies in clinical trials of human T and B cell malignancies. **Biological Response Modifiers Program**. Proceedings of the Retreat on Monoclonal Antibodies in Therapeutic Trials. Frederick, Maryland, pp. 53–55, 1982.

13. Miller RA, Maloney D, Warnke R, McDougall R, Wood G, Kawakami T, Dilley J, Goris ML and Levy R: Considerations for treatment with hybridoma antibodies. **Hybridomas in Cancer Diagnosis and Treatment**. MS Mitchell and HF Oettgen (eds.), Raven Press, New York, pp. 133–145, 1982.
14. Levy R: Monoclonal antibodies: Sixth Annual Cancer Symposium, Scripps Memorial Hospital, 1982.

1983

15. Finn OJ, Sung E, Jones P and Levy R: Two alpha chains and three beta chains of human Ia antigen. **In: Ir Genes: Past Present and Future**. CW Pierce, SE Cullen JA Kapp, BD Schwartz and DC Shreffler, editors. Humana Press, Clifton, NJ, pp. 203–207, 1983.
16. Levy R, Stratte PT, Link MP, Oseroff A, Maloney DG and Miller RA: Monoclonal antibodies in leukemia therapy. **Leukemia Research: Advances in Cell Biology and Treatment**. SB Murphy and JR Gilbert, editors. Elsevier Science Publishing Co., pp. 269–279, 1983.
17. Hurley CK, Nunez G, Winchester R, Finn O, Levy R, Stastny P and Capra JD: Partial structural characterization of human HLA-DR subsets using monoclonal antibodies. **Hybridomas and Cellular Immortality**. BH Tom and JP Allison, editors. Plenum Publishing Corporation, NY, pp. 83–100, 1983.
18. Levy R, Miller RA, Stratte PT, Maloney DG, Link MP, Meether TC, Oseroff A, Thielemans K and Warnke R: Therapeutic trials of monoclonal antibody in leukemia and lymphoma: Biologic considerations. **Monoclonal Antibodies and Cancer**. RE Langman, IS Trowbridge and R. Dulbecco, editors. Academic Press, NY, pp. 5–16, 1983.
19. Levy R and Miller RA: Biological and clinical implications of lymphocyte hybridomas: Tumor therapy with monoclonal antibodies. **Ann Rev Med** 34:107–116, 1983.
20. Levy R: Monoclonal antibodies in cancer therapy. **Clinical Immunology Today**, No. 3., pp. 1–7. July 1983.

1984

21. Levy R, Stratte P, Link M, Maloney DG, Oseroff A and Miller RA: Monoclonal antibodies to human lymphocytes. **Monoclonal Antibodies and Functional Cell Lines**. Chapter 8. RH Kennett, KB Bechtol and TJ McKearn (eds.), Plenum Publishing Corporation, New York, pp. 193–214, 1984.

1985

22. Levy R: Biologicals for cancer treatment: Monoclonal antibodies. **Cancer: Progress and Prospects XXVII. Hospital Practice**, pp. 67–92, November 15, 1985.
23. Lowder JN and Levy R: Monoclonal antibodies—therapeutic and diagnostic uses in malignancy. **Western J Med** 143:810-818, December 1985.
24. Miller RA and Levy R: Functional and surface marker characteristics. **Immunoglobulin: A Tumor Specific Antigen for Human B Cell Lymphoma**. Academic Press, 1985.

25. Lowder JN, Meeker TC and Levy R: Monoclonal antibody therapy of lymphoid malignancy. **Cancer Surveys** 4:359–375, 1985.

1986

26. Levy R, Meeker T, Lowder J, Maloney D, Thielemans K, Gralow J, Warnke RA, Miller RA, Cleary ML and Sklar J: The immunobiology of B cell lymphoma studies with anti-idiotypic antibodies. **Symposium on Fundamental Cancer Research**, Vol. 38, pp. 261–268, 1986, University of Texas System Cancer Center.

1987

27. Levy R: Monoclonal antibodies: Clinical trials and new insights into tumour biology. **A Perspective on Biology and Medicine in the Twenty-First Century**, Royal Society of Medicine Services Limited, Series 121, pp. 103–112, 1987.
28. Levy R, Levy S, Brown SL, Kon S and Carroll W: Anti-idiotypic antibodies reveal the existence of somatic mutation in human B cell lymphoma. **Monographs in Allergy**. P Dukor, LA Hanson, P Kallos, F Shakib, Z Trnka and BH Waksman (eds.), S. Karger, Basel, 22:194–203, 1987.
29. Levy R, Levy S, Cleary ML, Carroll W, Kon S, Bird J and Sklar J: Somatic mutation in human B cell tumors. **Immunological Reviews** 96:43–58, Munksgaard, Copenhagen, 1987.
30. Levy R: Will monoclonal antibodies find a place in our therapeutic armamentarium? **J Clin Oncology** 5:527–529

1989

31. Brown SL, Miller RA and Levy R: Anti-idiotypic antibody therapy of B-cell lymphoma. **Seminars in Oncology** 16:199–210, 1989.
32. Campbell MJ, Esserman L, Byars NE, Allison AC and Levy R: Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. **Intern. Rev. Immunol** 4:251, 1989.

1990

33. Levy, R. and Miller RA: Therapy of lymphoma directed at idiotypes. **NCI Monographs**, 10:61–68, 1990.
34. Miller R and Levy R: Radiolabeled antibodies: Another form of cytotoxic treatment. **J Clin Onc** 9:537–538, 1990.
35. Kwak LW, Campbell M, and Levy R. Idiotypic vaccination post-bone marrow transplantation for B-cell lymphoma: Initial Studies in a murine model. **Cancer Detection and Prevention** 15:323–325, 1990.

36. Levy R: Anti-idiotypes: Therapy and somatic mutation of human B cell tumors. **Immunology for the Practicing Physician**. Bozell, Jacobs, Kenyon and Echardt, Inc., New York, 1990.
37. Campbell MJ, Brown SL and Levy R: Tumor immunology and immunotherapy. **Immunology Scope Monograph**. Upjohn Co., Kalamazoo, Michigan, 1990.
38. Levy R and Miller RA: Antibodies in cancer therapy: B cell lymphomas. **Biologic Therapy of Cancer: Principles and Practice**, S Hellman, V DeVita and SA Rosenberg (eds), Lippincott, 1990.

1991

39. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Nelp WB, Levy R, Miller R, Fisher D, Matthews D, and Bernstein ID: Radiolabeled antibody therapy of human B cell lymphomas. **Immunobiology of Proteins and Peptides VI**, M.Z. Atassi (ed), Plenum Press, 1991.

1992

40. Bahler DW, Zelenetz AD, Chen TT and Levy R. Antigen selection in human lymphomagenesis. **Cancer Research (Suppl)** 52:5547a–5551s, 1992.
41. Maloney DG, Levy R, and Miller RA. Monoclonal anti-idiotypic antibody therapy of lymphoma. **Biologic Therapy of Cancer Update**, V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), J.B. Lippincott Company, Philadelphia, PA, 1992.

1993

42. Renschler MF and Levy R. Overcoming the limitations of chemotherapy in the treatment of B-cell Non-Hodgkin's lymphomas—An approach using radiolabeled peptide ligands. **Western J. Med.** 158:530–532, 1993.

1994

43. Maloney DG, Levy R, and Campbell MJ. Antibodies. **The Molecular Basis of Cancer**, J. Mendelsohn, PM Howley, MA Israel, LA Liotta (eds.), WB Saunders, Harcourt Brace Jovanovich, Inc. , Philadelphia, PA. 1994

1995

44. Renschler MF, Dower WJ, Levy R. Identification of Peptide Ligands for the Antigen Binding Receptor Expressed on Human B-Cell Lymphomas. **Combinatorial Peptide Libraries, Methods in Molecular Biology**, Humana Press, Inc., Totowa, NJ. 1995

1997

45. Hsu F, Engleman E and Levy R. Dendritic cells and their application in immunotherapeutic approaches to cancer therapy. **PPO Updates**, Vol 11, No. 5, 1997
46. Reichardt V, Okada C, Stockerl-Goldstein K, Bogen B, and Levy R. Rationale for adjuvant idiotypic vaccination after high dose therapy for multiple myeloma. **Biology of Blood & Marrow Transplantation**, 3:157-163, 1997

47. Maecker HT, Syrengelas A and Levy R. Cytokine fusion constructs as DNA vaccines against tumors. **Methods in Molecular Medicine**, 29:221-239, 1997

1998

48. Timmerman J and Levy R. Melanoma vaccines: Prim and proper presentation. **Nature Medicine**, 4:6-7, 1998.

1999

49. Timmerman JM and Levy R. Dendritic cell vaccines for cancer immunotherapy. **Ann Rev of Med**, 50:507-529, 1999.
50. Levy R. Karnofsky Lecture: Immunotherapy of lymphoma. **J. Clinical Oncology**. 17(11 Suppl):7-12, 1999.
51. Alizadeh A, Eisen M, Davis RE, Ma C, Sabet H, Tran T, Powell JI, Yang L, Marti GE, Moore DT, Hudson JR Jr, Chan WC, Greiner T, Weisenburger D, Armitage JO, Lossos I, Levy R, Botstein D, Brown PO, Staudt LM. Related Articles. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. *Cold Spring Harb Symp Quant Biol*. 64:71-8, 1999.

2000

52. Levy, R. A perspective on monoclonal antibody therapy: Where we have been and where we are going. **Seminars in Hematology**, 37 (suppl. 7), 2000.
53. Timmerman J, and Levy R. The history of the development of vaccines for the treatment of lymphoma. **Clinical Lymphoma**, 1(2): 129-139, 2000.
54. Levy, R. Monoclonal antibodies for the treatment of lymphoma; many different ways to use a new modality. **Hematology 2000**, 397-400, 2000.

2001

55. Reddy SA, Okada C, Wong C, Bahler D, Levy R. T cell antigen receptor vaccines for active therapy of T cell malignancies. *Cutaneous T Cell Lymphoma: Basic and Clinically Relevant Biology*, *Ann N Y Acad Sci*. 941:97-105, 2001.
56. Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Immunotherapy of Non-Hodgkin's Lymphomas, **Hematology (Am Soc Hematol Educ Program)** 221-40, 2001.

2002

57. Lossos IS and Levy, R. Higher-grade transformation of follicle center lymphoma: phenotypic tumor progression associated with diverse genetic lesions. *Seminars in Cancer Biology*. In press 2002.

2003

58. Lossos IS and Levy R. Diffuse Large B-cell Lymphoma: insights gained from gene expression profiling. *International Journal of Hematology*. In press.